Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606649 | 0.84 | MEN1 (0.39) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL4606120 | 0.82 | MEN1 (0.37) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL4953601 | 0.81 | — | — | |
| SCHEMBL1237159 | 0.81 | MEN1 (0.57) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL29485576 | 0.81 | MEN1 (0.57) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL6763575 | 0.80 | ESR1 (0.43) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL4952371 | 0.77 | — | — | |
| SCHEMBL4607784 | 0.76 | — | — | |
| SCHEMBL4954657 | 0.75 | ERN1 (0.31) | — | |
| SCHEMBL14829735 | 0.75 | MEN1 (0.71) | MEN1KMT2APOLBGAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456323-B2 | 1,3-bis(3-formyl-4-hydroxyphenyl)adamantanes and polynuclear polyphenols derived therefrom | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080242896-A1 | 1,3-Bis(3-Formyl-4-Hydroxyphenyl)Adamantanes and Polynuclear Polyphenols Derived Therefrom | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2008-10-02 | — | — | US | disclosed |
| EP-1336597-B1 | Hydroxyphenyl adamantanes and process for the production of the same | HONSHU CHEMICAL IND (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-6720460-B2 | FORMING HEAT RESISTANT, MECHANICAL STRENGTH POLYMER ADDITIVES; ACID CATALYZED REACTION OF ADAMANTANE DIOL OR TRIOL WITH PHENOLIC DERIVATIVE | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030187307-A1 | Hydroxyphenyl adamantanes and process for the production of the same | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1336597-A1 | Hydroxyphenyl adamantanes and process for the production of the same | Honshu Chemical Industry Co., Ltd. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187307-A1 | Hydroxyphenyl adamantanes and process for the production of the same | CYP8B1, DHPS, P4HA1 | MEN1 1025/4885KMT2A 4019/4885POLB 727/4885 |
| US-20080242896-A1 | 1,3-Bis(3-Formyl-4-Hydroxyphenyl)Adamantanes and Polynuclear Polyphenols Derived Therefrom | HNMT, NEFM, CD69 | MEN1 4682/4885KMT2A 2847/4885POLB 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.